Fresenius Nod In EU Adds To Crowded Adalimumab Market
Fresenius Kabi has become the latest firm to receive a nod for a European biosimilar rival to Humira, adding to an already crowded biosimilar adalimumab market.
You may also be interested in...
Fresenius Kabi’s biosimilar pegfilgrastim rival to Neulasta has been accepted for review by the European Medicines Agency. The firm believes the “milestone” application will pave the way for a 2021 launch.
With quarterly sales up to $36m, Biogen says its Imraldi rival to Humira is the market-leading adalimumab biosimilar in Europe.
Biosimilar adalimumab rivals to AbbVie’s Humira blockbuster continue to take market share in Germany, the latest market data demonstrates.